56
G. Guchhait, A.K. Misra / Catalysis Communications 14 (2011) 52–57
hot plate. Silica gel 230–400 mesh was used for column chromatog-
raphy. 1H and 13C NMR spectra were recorded on Brucker Advance
DPX 200 MHz using CDCl3 as solvent and TMS as internal reference
unless stated otherwise. Chemical shift value is expressed in δ ppm.
ESI-MS were recorded on a Micromass Quttro II mass spectrometer.
Commercially available grades of organic solvents of adequate purity
are used in all reactions.
4.2.5. Cyclopentyl 2,3,4,6-tetra-O-acetyl-α-D-Glucopyranoside (15)
1H NMR (200 Hz, CDCl3): δ 5.40 (t, J=9.8 Hz each, 1 H, H-3), 5.11
(d, J=3.8 Hz, 1 H, H-1), 4.94 (t, J=9.8 Hz each, 1 H, H-4), 4.74
(dd, J=9.8, 3.8 Hz, 1 H, H-2), 4.26–3.99 (m, 3 H, H-5, H-6ab), 3.67–
3.60 (m, 1 H, –CH), 2.04, 1.98, 1.97, 1.95 (4 s, 12 H, 4 COCH3), 1.70–
1.45 (m, 8 H); 13C NMR (50 MHz, CDCl3): δ 170.6, 170.1, 169.6, 169.4
(4 COCH3), 94.3 (C-1), 81.5, 71.4, 70.9, 70.3, 67.2, 62.1, 33.1, 31.8, 23.3,
22.9, 20.7 (2 C), 20.6 (2 C) (4 COCH3); ESI-MS: 439.1 [M+Na]+
.
4.2. Typical procedure for the Fischer glycosylation
4.2.6. 2-Butyl 2,3,4,6-tetra-O-acetyl-α-D-Glucopyranoside (16)
To a suspension of D-glucose (0.9 g, 5.0 mmol) in benzyl alcohol
(2.0 mL, 20.0 mmol) was added sulfamic acid (100 mg, 1.0 mmol) at
room temperature and the neat reaction mixture was allowed to stir
at 80 °C for 5 h (Table 1). After completion of the reaction, the solvents
was removed under pressure and the crude product was passed
through a short pad of silica using CH2Cl2-CH3OH (20:1) to furnish
pure compound 6 (1.1 g, 81%). In order to prepare the analytical
sample for NMR spectral analysis, excess benzyl alcohol was removed
from the reaction mixture and acetic anhydride (3.0 mL) was added to
it and the reaction mixture was allowed to stir at 60 °C for 2 h. The
solvents were removed under reduced pressure and the crude
product was passed through a short pad of silica using hexane-
EtOAc (3:1) to furnish pure acetylated compound 6. Following the
similar reaction methodology a series of alkyl glycosides were
prepared in excellent yield. All products were acetylated for their
characterization by NMR spectral analysis. Selected spectral data of
compounds are presented below.
1H NMR (200 Hz, CDCl3): δ 5.47 (t, J=10.2 Hz each, 1 H, H-3), 5.18
(d, J=3.7 Hz, 1 H, H-1), 5.05 (t, J=10.2 Hz each, 1 H, H-4), 4.82
(dd, J=10.1, 3.7 Hz, 1 H, H-2), 4.24–4.22 (m, 1 H, H-6a), 4.15–4.07
(m, 2 H, H-5, H-6b), 3.69–3.60 (m, 1 H, CH), 2.08, 2.03, 2.00 (3 s, 12 H,
4 COCH3), 1.24-1.21 (m, 2 H, CH2), 1.09 (d, J=6.0 Hz, 3 H, CH3), 0.88
(t, J=7.4 Hz each, 3 H, CH3); 13C NMR (50 MHz, CDCl3): δ 170.7 (2 C),
170.2, 169.7 (4 COCH3), 95.7 (C-1), 78.2, 72.9, 71.1, 70.2, 68.7, 62.2,
24.9, 20.8 (2 C), 20.6 (2 C) (4 COCH3), 19.2, 10.3; ESI-MS: 427.1
[M+Na]+
.
4.2.7. 2-Propyl 2,3,4,6-tetra-O-acetyl-α-D-Glucopyranoside (17)
1H NMR (200 Hz, CDCl3): δ 5.46 (t, J=9.8 Hz each, 1 H, H-3), 5.17
(d, J=3.9 Hz, 1 H, H-1), 5.02 (t, J=9.8 Hz each, 1 H, H-4), 4.79
(dd, J=9.8, 3.8 Hz, 1 H, H-2), 4.25–4.21 (m, 1 H, H-5), 4.12–4.05 (m, 2
H, H-6ab), 3.92–3.83 (m, 1 H, CH), 2.08, 2.04, 2.02, 2.00 (4 s, 12 H, 4
COCH3), 1.23–1.20 (m, 3 H, CH3), 1.13–1.10 (m, 3 H, CH3); 13C NMR
(50 MHz, CDCl3): δ 170.8, 170.3, 170.2, 169.7 (4 COCH3), 94.2 (C-1),
71.5, 71.0, 70.2, 68.8, 67.1, 62.2, 23.1, 21.6, 20.7 (2 C), 20.6 (2 C)
4.2.1. 1-Butyl 2,3,4,6-tetra-O-acetyl-α-D-Glucopyranoside (9)
(4 COCH3); ESI-MS: 413.1 [M+Na]+
.
1H NMR (200 Hz, CDCl3): δ 5.38 (t, J=10.0 Hz each, 1 H, H-3),
5.07–4.91 (m, 2 H, H-1, H-4), 4.75 (dd, J=10.2, 3.6 Hz, 1 H, H-2),
4.24–4.15 (m, 1 H, H-5), 4.08–3.90 (m, 2 H, H-6ab), 3.68–3.57 (m, 1 H,
OCH2a), 3.42–3.31 (m, 1 H, OCH2b), 2.02, 1.99, 1.96, 1.94 (4 s, 12 H, 4
COCH3), 1.60-1.52 (m, 2 H, CH2), 1.46-1.30 (m, 2 H, CH2), 0.84
(t, J=7.2 Hz each, 3 H, CH3); 13C NMR (50 Hz, CDCl3): δ 170.5, 170.0,
169.5, 169.3 (4 COCH3), 95.7 (C-1), 71.1, 70.4, 68.8, 68.5, 67.3, 62.0,
4.2.8. 3-Pentyl 2,3,4,6-tetra-O-acetyl-α-D-Glucopyranoside (18)
1H NMR (200 Hz, CDCl3): δ 5.52 (t, J=9.8 Hz each, 1 H, H-3), 5.14
(d, J=3.8 Hz, 1 H, H-1), 4.96 (t, J=9.8 Hz each, 1 H, H-4), 4.83
(dd, J=9.8, 3.8 Hz, 1 H, H-2), 4.26–4.04 (m, 3 H, H-5, H-6ab), 3.48–
3.36 (m, 1 H, CH-), 2.09, 2.03, 2.01, 1.98 (4 s, 12 H, 4 COCH3), 1.62–1.43
(m, 4 H, 2 CH2CH3), 0.94–0.82 (m, 6 H, 2 CH2CH3); 13C NMR (50 MHz,
CDCl3): δ 170.6, 170.1, 169.7, 169.3 (4 COCH3), 95.1 (C-1), 82.5, 71.7,
71.5, 70.3, 67.4, 62.2, 26.7, 25.3, 20.7 (4 C, 4 COCH3), 9.9, 9.5; ESI-MS:
29.8, 20.8 (2 C), 20.7 (2 C), 19.3, 13.9; ESI-MS: m/z=427.1 [M+Na]+
.
4.2.2. 2-Chloroethyl 2,3,4,6-tetra-O-acetyl-α-D-Glucopyranoside (10)
441.1 [M+Na]+
.
1H NMR (200 Hz, CDCl3): δ 5.39 (dd, J=10.2 Hz each, 1 H, H-3),
5.08 (d, J=3.8 Hz, 1 H, H-1), 4.92 (t, J=10.1 Hz each, 1 H, H-4), 4.78
(dd, J=10.2, 3.8 Hz, 1 H, H-2), 4.24–3.99 (m, 3 H, H-5, H-6a,b), 3.93–
3.82 (m, 1 H, OCH2a), 3.77-3.52 (m, 3 H, OCH2), 2.02, 1.99, 1.96, 1.94
(4 s, 12 H, 4 COCH3); 13C NMR (50 Hz, CDCl3): δ 171.5, 170.1, 169.9,
169.5 (4 COCH3), 96.2 (C-1), 70.8, 70.1, 69.0, 68.5, 67.8, 61.9, 42.5, 20.7
4.2.9. 2-Octyl 2,3,4,6-tetra-O-acetyl-α-D-Glucopyranoside (19)
1H NMR (200 Hz, CDCl3): δ 5.45 (t, J=9.6 Hz each, 1 H, H-3), 5.10
(d, J=3.4 Hz, 1 H, H-1), 4.96 (t, J=9.6 Hz each, 1 H, H-4), 4.82
(dd, J=9.6, 3.4 Hz, 1 H, H-2), 4.27–4.03 (m, 3 H, H-5, H-6ab), 3.70–
3.60 (m, 1 H, CH), 2.04, 2.02, 2.00, 1.98 (4 s, 12 H, 4 COCH3), 1.54–1.15
(m, 10 H), 1.10 (d, J=6.1 Hz, 3 H, CH3), 0.84 (t, J=6.6 Hz, 3 H, CH3);
13C NMR (50 MHz, CDCl3): δ 170.8, 170.5, 169.8, 169.6 (4 COCH3), 96.1
(C-1), 73.1, 71.8, 71.5, 70.5, 68.9, 62.4, 36.9, 32.0, 25.5, 22.8, 21.7, 20.7
(4C; 4 COCH3); ESI-MS: m/z=433.1 [M+Na]+
.
4.2.3. 4-Pentenyl 2,3,4,6-tetra-O-acetyl-α-D-Glucopyranoside (11)
1H NMR (200 Hz, CDCl3): δ 5.88–5.71 (m, 1 H, CH=CH2), 5.47
(t, J=9.6 Hz each, 1 H), 5.15–4.99 (m, 4 H, H-1, H-4, CH=CH2), 4.84
(dd, J=10.0, 3.6 Hz, 1 H, H-2), 4.31–4.23 (m, 1 H, H-5), 4.16–3.99
(m, 2 H, H-6ab), 3.78–3.67 (m, 1 H, OCH2a), 3.56–3.40 (m, 1 H, OCH2b),
2.11, 2.06, 2.0, 1.99 (4 s, 12 H, 4 COCH3), 2.0–1.90 (m, 2 H, CH2), 1.77–
1.67 (m, 2 H, CH2); 13C NMR (50 Hz, CDCl3): δ 170.5, 170.0, 169.5,
169.3 (4 COCH3), 137.7, 115.4, 95.8 (C-1), 71.0, 70.3, 68.7, 67.9, 67.3,
(4 C, 4 COCH3), 19.9, 14.2; ESI-MS: 483.2 [M+Na]+
.
4.2.10. Cyclopentyl 2,3,4,6-tetra-O-acetyl-α-D-Mannopyranoside (25)
1H NMR (200 Hz, CDCl3): δ 5.38 (dd, J=10.0, 3.3 Hz, 1 H, H-3),
5.24 (t, J=9.9 Hz each, 1 H, H-4), 5.14–5.12 (m, 1 H, H-2), 4.85 (br s, 1
H, H-1), 4.27–4.01 (m, 3 H, H-5, H-6ab), 3.51–3.31 (m, 1 H, CH), 2.10,
2.04, 1.99, 1.94 (4 s, 12 H, 4 COCH3), 1.57–0.76 (m, 8 H); 13C NMR
(50 MHz, CDCl3): δ 170.6, 169.9, 169.8, 169.4 (4 COCH3), 96.5 (C-1),
81.7, 70.2, 68.7, 68.2, 66.3, 62.6, 26.6, 25.3, 20.9, 20.6 (2 C), 20.3
62.0, 30.2, 28.6, 20.7 (4C, 4 COCH3); ESI-MS: m/z=439.1 [M+Na]+
.
4.2.4. Cyclohexyl 2,3,4,6-tetra-O-acetyl-α-D-Glucopyranoside (14)
(4 COCH3), 9.9, 9.0; ESI-MS: 439.1 [M+Na]+
.
1H NMR (200 Hz, CDCl3): δ 5.38 (t, J=10.0 Hz each, 1 H, H-3), 5.08
(d, J=3.9 Hz, 1 H, H-1), 4.86 (t, J=10.0 Hz each, 1 H, H-4), 4.67 (dd,
J=10.0, 3.8 Hz, 1 H, H-2), 4.16–3.91 (m, 3 H, H-5, H-6ab), 3.57–3.43
(m, 1 H), 1.99, 1.93, 1.91, 1.90 (4 s, 12 H, 4 COCH3), 1.82-1.61 (m, 4 H),
1.40-1.15 (m, 6 H); 13C NMR (50 Hz, CDCl3): δ 170.5, 170.0, 169.5,
169.0 (4 COCH3), 94.0 (C-1), 76.8, 71.1, 70.3, 68.8, 67.2, 62.0, 33.2,
31.6, 25.6, 24.0, 23.7, 20.7 (4 C, 4 COCH3); ESI-MS: m/z=453.1
4.2.11. Cyclohexyl 2,3,4,6-tetra-O-acetyl-α-D-Mannopyranoside (26)
1H NMR (200 Hz, CDCl3): δ 5.36 (dd, J=10.0, 3.3 Hz, 1 H, H-3),
5.23 (t, J=9.9 Hz each, 1 H, H-4), 5.16–5.15 (m, 1 H, H-2), 4.92 (br s, 1
H, H-1), 4.26–4.21 (m, 1 H, H-6a), 4.12–4.03 (m, 2 H, H-5, H-6b), 3.59–
3.51 (m, 1 H, CH), 2.12, 2.06, 2.01, 1.96 (4 s, 12 H, 4 COCH3), 1.84–0.66
(m, 4 H), 1.50–1.18 (m, 6 H); 13C NMR (50 MHz, CDCl3): δ 170.6,
170.2, 169.9, 169.8 (4 COCH3), 95.8 (C-1), 76.7, 70.3, 69.2, 68.4, 66.5,
[M+Na]+
.